“Effects elicited by d‐phenylalanine were completely blunted by co‐administration of acetazolamide , but not of 1‐N‐(4‐sulfamoylphenyl‐ethyl)‐2,4,6‐trimethylpyridinium perchlorate (C18), a CA inhibitor that, differently from acetazolamide, does not cross the blood brain barrier.”
“The effects elicited by d‐phenylalanine were blunted by co‐administration of acetazolamide , but not of C18.”